The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program has funded three investigators from NCCN Member Institutions—Patrick Boland, MD, and Sarbajit Mukherjee, MD, MS, both of Roswell Park Comprehensive Cancer Center; and Amit Mahipal, MBBS, of Mayo Clinic Cancer Center—to further evaluate the clinical effectiveness and safety of trifluridine and tipiracil (TAS-102) for the treatment of various advanced solid tumors. The grants are being administered through a collaborative scientific research relationship with Taiho Oncology, Inc.
Submissions were peer-reviewed by a Scientific Review Committee, which consisted of medical oncologists from NCCN Member Institutions. The studies are expected to start enrolling patients within the next 10 months and be completed within 2 years. ■
